Clinical and virological parameters of 27 HIV-infected individuals participating in the GS-US-183-0105 study of elvitegravir.

aMajor mutations associated with resistance to INSTI as described [4], [11].bPlasma HIV viral load (log10 copies/ml).INSTI-R, mutations associated with resistance to INSTI; PI (1), number of primary mutations associated with resistance to PI; PI (2), number of secondary mutations associated with resistance to PI; #TAMs, number of thymidine analogue-associated mutations; #NAMs, number of nucleoside analogue-associated mutations; NNRTI (1), number of primary mutations associated with resistance to NNRTI. EC50 FC, based on VIRALARTS™HIV three independent EC50 replicates for each drug were used to calculate the fold changes (FC) of the query viruses relative to the HIV-1NL4-3 control and the mean EC50 FC is indicated. MAX, complete virus inhibition was not achieved using the maximum drug concentration, i.e., virus was completely resistant to the respective antiretroviral drug.